SUMMARY
# Parkinson's Disease Subtype Classification — Precision Medicine Approach
## Background and Rationale
Parkinson's disease (PD) presents with remarkable clinical and biological heterogeneity, yet current diagnostic and therapeutic approaches treat it as a uniform condition. This heterogeneity manifests in variable motor and non-motor symptoms, differential rates of progression, and inconsistent treatment responses across patients. Recent advances in multi-omics technologies, neuroimaging, and di
METHODOLOGY NOTES
Phase 1 (Months 1-6): Recruit 800 participants including 600 PD patients (300 newly diagnosed, 300 established) and 200 age-matched controls from 10 movement disorder centers. Inclusion criteria: clinical PD diagnosis per MDS criteria, age 50-80, Hoehn-Yahr stages 1-3. Exclusion criteria: atypical parkinsonism, dementia (MoCA <24), significant comorbidities.
Phase 2 (Months 3-18): Comprehensive baseline assessment including MDS-UPDRS motor and non-motor evaluations, cognitive testing battery (MoCA, detailed neuropsychological assessment), DaTscan SPECT imaging, 3T MRI with structural, diffusion tensor, and resting-state functional sequences, collection of blood and CSF samples for multi-omics analysis, and deployment of wearable devices (smartwatch, smartphone) for 2-week continuous monitoring periods.
Phase 3 (Months 6-24): Process biological samples using standardized protocols for proteomics (TMT mass spectrometry), metabolomics (LC-MS/MS), and transcriptomics (RNA-seq). Analyze d